Current report
Open the filing on sec.gov
Scilex Holding Company (SCLX)
Nasdaq: SCLX · Biological Products, (No Diagnostic Substances) · Palo Alto, CA · filing with the SEC since 2020
The companyfiscal 2025, as filed
Revenue$30.3M-46.5%
Net incomen/a
Earnings per share$-36.48-353.2%
Operating cash flow$3.8M-80.3%
Cash$5.0M+51.4%
Debtn/a
Shareholders’ equity-$212M-9.9%
Shares, diluted11.0M-91.5%
Return on equityn/a
The recordfrom its filings
Filings in 202652
Newest filingSep 29 · 8-K
Annual reportApr 10, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted9
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Revenue $31.6MNet income -$465MCash from operations -$17.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Activist holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.